EUCTR2014-000130-37-IT进行中（未招募）1 期
Prospective, phase II study to evaluate the efficacy and the safety of a combination of bendamustine-melphalan as preparative regimen to autologous transplantation of hematopoietic cells for multiple myeloma who have relapsed after previous high-dose therapy
FONDAZIONE NEOPLASIE SANGUE ONLUS (FO.NE.SA. Onlus)0 个研究点目标入组 73 人开始时间: 2014年2月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 73
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age = 18 = 70 years.
- •Multiple myeloma patients who have relapsed after first-line therapy including ASCT (single or tandem) with an interval between the last ASCT and clinical relapse of at least 12 months.
- •At least stable disease after = 4-6 cycles of salvage treatment (see specific chapter in the protocol)
- •Performance of patient screening between 30 and 90 days after the end of salvage treatment
- •Measurable myeloma defined by M-protein > 1000 mg/dL if IgG or 500 mg/dL if IgA or Bence Jones protein > 200 mg/24 h or free light chain > 100 mg/L or measurable extramedullary plasmacytoma > 2 cm at the time of relapse and before the beginning of salvage treatment.
- •Collection of at least 3 x 106/Kg autologous hematopoietic stem cell (harvested at any time)
- •HCT-CI = 5
- •Adequate cardiac function with left ventricular ejection fraction = 50%.
- •Adequate renal function with Clearance creatinine = 50 ml/min
- •Adequate hepatic function with serum bilirubin <1,5 mg/L and AST and ALT values < 100 UI/L.
- •Adequate pulmonary function with DLCO > 30% and/or no need of supplementary oxygen.
- •Able to adhere to the study visit schedule and other protocol requirement.
- •Disease free of prior malignancies for at least 2 years.
- •Women of child bearing potential and male patients whose partner is a woman of child bearing potential must be prepared to use effective methods of contraception both before and during protocol treatment, or commit to absolute and continuous abstinence. Men must not father a child for up to 6 months following cessation of treatment and must use condoms.
- •Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 26
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 26
排除标准
- •Early relapse defined by an interval between the last ASCT and clinical relapse requiring salvage treatment < 12 months.
- •Progression after = 3 cycles of salvage treatment.
- •Plasma cell leukaemia.
- •SNC myeloma localization.
- •Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
- •Any active infection (e.g. failure to resolve previous infections or new infections)
- •Pregnant or breast feeding females.
- •Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
- •Positive serologic markers for human immunodeficiency virus (HIV).
- •Acute hepatitis B virus (HBV) with positive HBsAg and/or HBV-DNA. Patients having negative HBV-DNA, but with HBcAb positive serology, will not be excluded from the study and be given Lamivudine (100 mg /die) as prophylaxis starting one week before chemotherapy. HbsAg and AST/ALT and HBVDNA will be monitored every three weeks. Lamivudine therapy should be continued for one year after the end of therapy.
- •Acute hepatitis C virus (HCV) infection with positive HCV-RNA.
- •Major surgery less than 30 days before start of treatment.
- •Patients not agreeing to take adequate contraceptive measures during the study.
- •Any active, uncontrolled infection.
研究者
相似试验
招募中
不适用
The study evaluate the efficacy of intraoperative radiotherapy those who underwent neoadjuvant chemotherapy for pancreatic cancer.KCT0005113Yonsei University Health System, Gangnam Severance Hospital80
进行中（未招募）
1 期
Phase II Study for the Evaluation of the Efficacy of Gemcitabine plus Erlotinib in Rash-positive Patients with metastatic pancreatic cancer and good risk factorsmetastatic pancreatic carcinomaMedDRA version: 18.1Level: LLTClassification code 10033576Term: Pancreas carcinomaSystem Organ Class: 100000004864EUCTR2011-005471-17-DEKlinikum der Universität München-Großhadern150
进行中（未招募）
不适用
Prospective phase II trial evaluating efficacy of Trastuzumab therapy in HER2 FISH positive and/or HER2 mutation positive, pretreated, Non-Small Cell Lung Cancer patients (MO20509) - NDEUCTR2007-003709-29-ITISTITUTO CLINICO HUMANITAS
进行中（未招募）
1 期
A randomized study to explore the efficacy and feasibility of rotations between sunitinib and everolimus versus sequential treatment of sunitinib and everolimus until progression in patients with renal cancer.EUCTR2012-001337-13-ESAPRO115
进行中（未招募）
1 期
A randomized study to explore the efficacy and feasibility of rotations between sunitinib and everolimus versus sequential treatment of sunitinib and everolimus until progression in patients with renal cancer.Metastatic clear cell renal cancerMedDRA version: 14.1Level: LLTClassification code 10038416Term: Renal clear cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001337-13-GRAPRO115